
Investors Face August 10 Deadline in Erasca Securities Class Action
Investors who suffered significant losses in Erasca, Inc. have until August 10, 2026, to file for lead plaintiff status in a class action lawsuit. The litigation targets the biotech firm for allegedly misleading shareholders about the competitive standing and safety profile of its lead cancer drug, ERAS-0015.





















